Menopause and the Endocrine System: Hormones & Management
This paper reviews the relationship between the endocrine system and menopause, exploring the physiological changes that occur as women transition out of their reproductive years. It examines how declining estrogen and progesterone production triggers a range of physical and emotional symptoms during perimenopause, a transition that can last up to 14 years. The paper also discusses how environmental endocrine-disrupting chemicals may be lowering the age of menopause onset, and surveys evidence-based treatment options including hormonal therapies (systemic estrogen, progestogen) and nonhormonal pharmacological alternatives such as paroxetine and venlafaxine. The review underscores the importance of understanding menopause within its endocrine context to better support women's health during this life transition.
- Overview of Menopause: Definition, diagnosis, and age of onset
- The Role of Hormones in Menopause: Hormonal decline and symptom diversity
- Environmental Factors and Early Menopause Onset: EDCs and earlier perimenopause onset
- Management of Menopausal Symptoms: Hormonal and nonhormonal treatment options
- Conclusion: Summary of findings and treatment evidence
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its discussion in a clear definition of menopause at the outset, establishing precise clinical and biological parameters before moving to symptom analysis and treatment.
- It integrates multiple peer-reviewed sources, including clinical guidelines and epidemiological research, lending credibility to its claims about symptom prevalence and environmental causes.
- The inclusion of endocrine-disrupting chemicals as a factor in early menopause onset shows awareness of emerging research, adding depth beyond a standard overview of the condition.
Key academic technique demonstrated
The paper demonstrates effective literature synthesis: rather than summarizing sources one by one, it weaves multiple citations together to build a coherent argument about how hormonal decline, environmental exposure, and treatment options are interconnected. This technique shows readers how to use sources as evidence for a thesis rather than as isolated summaries.
Structure breakdown
The paper follows a logical three-part structure: (1) a definition and epidemiological overview of menopause, (2) an analysis of hormonal mechanisms and contributing environmental factors, and (3) a survey of evidence-based treatments. An introduction frames the purpose and a conclusion synthesizes key findings. This format suits a short review paper and makes the argument easy to follow.
Overview of Menopause
Menopause marks the time in a woman's life when her menstrual cycles stop. Although menstrual cycles can become disrupted prior to the onset of menopause, the condition is diagnosed when there has not been a menstrual period for 12 months (Menopause Overview, 2023) and is defined as "the end of menstruation due to the loss of ovarian follicular activity" (Dawn, 2022, p. 253). The average age of onset of perimenopause — the period in which women's hormone production begins to fluctuate — is currently 51 years in the United States. This means the condition can begin when women are still in their 40s or even earlier, though the production of the hormones that drive menopause typically begins to decline during the early 30s (Dawn, 2022). Even though menopause is a natural biological condition that affects all women at some point in their lives, its physical and emotional symptoms can have a severe impact on multiple quality-of-life factors due to decreased hormone production (Menopause Overview, 2023).
The Role of Hormones in Menopause
The change in ovarian follicular activity and the associated decrease in hormone production that occurs during perimenopause results in infertility, but it also causes a number of symptoms, some or all of which can be severe (Dawn, 2022). In this regard, Goodman et al. (2011) emphasize that "hot flushes, fatigue, joint and muscle pain, headache, urinary problems, depression, and mood swings are all common symptoms" (p. 2). This is not to say that all women experience every one of these symptoms, but the menopausal transition period is characterized by fundamental changes in the production of hormones by the ovaries, which invariably cause some type of psychophysiological response. For example, the National Institute on Aging (2023) points out that "the menopausal transition affects each woman uniquely and in various ways. The body begins to use energy differently, fat cells change, and women may gain weight more easily" (Menopausal transition, para. 4).
In addition, the perimenopause transition period can last as long as 14 years, although the average duration is about 7 years (Menopausal transition, 2023). The gradual decline in the production of estrogen and progesterone by the ovaries can therefore affect women's well-being for an extended period. A growing body of research also indicates that the age of onset of menopause is decreasing for multiple reasons (Levine & Hall, 2023). While the precise reasons why women are experiencing perimenopause at earlier ages remain unclear, various environmental factors are believed to be largely responsible.
Conclusion
The research reviewed here confirms that menopause is a natural biological condition in women in which menstrual cycles stop due to the loss of ovarian follicular activity, typically occurring around age 51 in the United States. The hormonal changes that occur during perimenopause — a transition that can last up to 14 years — cause a variety of symptoms such as hot flushes, fatigue, joint and muscle pain, headache, urinary problems, depression, and mood swings. The age of onset of perimenopause appears to be decreasing, which may be attributable in part to environmental factors such as endocrine-disrupting chemicals. Various treatments are available for perimenopausal symptoms, including lifestyle changes and hormone therapies such as estrogen and progestogen. Nonhormonal treatments such as paroxetine and venlafaxine also have proven efficacy in reducing menopausal transition symptoms.
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023). Management of menopausal symptoms: A review. JAMA, 329(5), 405–420.
Dawn, D. (2022). A qualitative study exploring post-menopausal women's perceptions and experiences of menopause. Indian Journal of Health & Wellbeing, 13(2), 253–257.
Goodman, N. F. et al. (2011). American Association of Clinical Endocrinologists' medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocrine Practice, 17, 1–25.
Levine, L., & Hall, J. E. (2023). Does the environment affect menopause? A review of the effects of endocrine disrupting chemicals on menopause. Climacteric, 1–10.
Menopause Overview. (2023). Mayo Clinic. Retrieved from https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397
Menopausal transition. (2023). National Institute on Aging. Retrieved from https://www.nia.nih.gov/health/what-menopause
Always verify citation format against your institution’s current style guide requirements.